November 6, 2017 06:28 AM EST

For 3rd time, the FDA and its new commissioner dropped safety issues and trial demands, clearing the path for snubbed therapy

John Carroll

Editor & Founder

TherapeuticsMD $TXMD was slammed on May 8 when the FDA formally rejected its application for a vaginal pain medicine dubbed TX-004HR. Regulators wanted more …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

For 3rd time, the FDA and its new commissioner dropped safety issues and trial demands, clearing the path for snubbed therapy

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

For 3rd time, the FDA and its new com­mis­sion­er dropped safe­ty is­sues and tri­al de­mands, clear­ing the path for snubbed ther­a­py

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

For 3rd time, the FDA and its new commissioner dropped safety issues and trial demands, clearing the path for snubbed therapy